Alumis (ALMS) Projected to Post Quarterly Earnings on Wednesday

Alumis (NASDAQ:ALMS) is anticipated to announce its earnings results before the market opens on Wednesday, June 18th. Analysts expect the company to announce earnings of ($1.47) per share for the quarter.

Alumis (NASDAQ:ALMS) last released its earnings results on Wednesday, May 14th. The company reported ($1.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.47) by ($0.35). On average, analysts expect Alumis to post $-9 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Alumis Stock Down 2.0%

ALMS stock opened at $3.36 on Wednesday. Alumis has a 52 week low of $3.18 and a 52 week high of $13.53. The business has a 50-day simple moving average of $5.06 and a 200 day simple moving average of $6.17.

Analyst Ratings Changes

Several research analysts have commented on ALMS shares. Guggenheim began coverage on shares of Alumis in a research report on Tuesday. They set a “buy” rating and a $18.00 price objective for the company. Oppenheimer lowered their price target on Alumis from $26.00 to $25.00 and set an “outperform” rating for the company in a report on Thursday, May 15th. Cantor Fitzgerald restated an “overweight” rating on shares of Alumis in a research report on Thursday, March 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $14.00 target price on shares of Alumis in a report on Wednesday, April 30th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $22.86.

Insider Buying and Selling at Alumis

In other Alumis news, major shareholder Foresite Labs, Llc purchased 20,000 shares of the company’s stock in a transaction dated Tuesday, May 6th. The stock was purchased at an average price of $4.34 per share, with a total value of $86,800.00. Following the completion of the purchase, the insider now owns 4,247,670 shares of the company’s stock, valued at approximately $18,434,887.80. The trade was a 0.47% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Alan Colowick purchased 16,104 shares of the business’s stock in a transaction dated Tuesday, April 1st. The shares were acquired at an average price of $6.97 per share, for a total transaction of $112,244.88. Following the acquisition, the director now owns 16,104 shares of the company’s stock, valued at $112,244.88. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders bought 397,044 shares of company stock worth $1,891,895.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Jane Street Group LLC bought a new stake in shares of Alumis in the 1st quarter valued at about $111,000. Goldman Sachs Group Inc. boosted its holdings in Alumis by 24.0% in the first quarter. Goldman Sachs Group Inc. now owns 61,645 shares of the company’s stock valued at $378,000 after acquiring an additional 11,949 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Alumis by 64.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company’s stock valued at $77,000 after purchasing an additional 4,926 shares during the period. Finally, Rhumbline Advisers raised its holdings in Alumis by 21.7% during the 1st quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock worth $102,000 after purchasing an additional 2,949 shares during the last quarter.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.